Steve Pearson, ICER president (Jeff Rumans)

A rar­i­ty for ICER: Cost watch­dog says Covid-19 ther­a­peu­tics ap­pro­pri­ate­ly priced in the US

Known as a fer­vent watch­dog over the prices and cost-ef­fec­tive­ness of new phar­ma­ceu­ti­cals, the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) said in a re­port pub­lished ear­ly Thurs­day that all four Covid-19 out­pa­tient treat­ments’ prices are ad­e­quate­ly aligned with their ben­e­fits.

The re­view cov­ered the on­ly mAb treat­ment that works against Omi­cron — GSK and Vir’s sotro­vimab — Pfiz­er’s high­ly ef­fec­tive pill Paxlovid, Mer­ck’s less ef­fec­tive pill mol­nupi­ravir and the cheap­er gener­ic drug flu­vox­am­ine, that has yet to re­ceive an EUA from FDA as a Covid-19 treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.